Aeolus Pharmaceuticals, Inc.
AOLS
$0.00
$0.000.00%
OTC PK
| 06/30/2017 | 03/31/2017 | ||||
|---|---|---|---|---|---|
| Revenue | -89.92% | 55.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -89.92% | 55.42% | |||
| Cost of Revenue | -28.45% | 21.47% | |||
| Gross Profit | 11.40% | -14.53% | |||
| SG&A Expenses | -5.79% | -16.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.35% | -0.51% | |||
| Operating Income | 8.31% | 4.78% | |||
| Income Before Tax | 8.31% | 4.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 8.31% | 4.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 8.31% | 4.78% | |||
| EBIT | 8.31% | 4.78% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 8.82% | 4.23% | |||
| Normalized Basic EPS | 9.30% | 4.44% | |||
| EPS Diluted | 0.00% | 0.00% | |||
| Normalized Diluted EPS | 9.30% | 4.44% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||